Company Filing History:
Years Active: 2017
Title: Innovations of Xiaoya Ping in Monoclonal Antibody Development.
Introduction
Xiaoya Ping is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on creating innovative solutions for treating various solid tumors.
Latest Patents
Xiaoya Ping holds a patent for a monoclonal antibody designed to antagonize and inhibit the binding of vascular endothelial growth factor (VEGF) to its receptor. This invention includes a mouse monoclonal antibody that targets VEGF and its receptor, along with the amino acid sequences for the heavy chain and light chain variable regions. The patent also outlines a humanized preparation process for the antibody, which can be utilized in pharmaceutical compositions. This humanized antibody or its derivatives can be administered alone or in combination with chemotherapy drugs for the treatment of solid tumors, including colon cancer, breast cancer, and rhabdomyosarcoma.
Career Highlights
Xiaoya Ping is associated with Suzhou Stainwei Biotech Inc., where he continues to advance his research and development efforts. His innovative work in monoclonal antibodies has the potential to significantly impact cancer treatment.
Collaborations
Xiaoya Ping collaborates with esteemed colleagues, including Shiping Luo and Hongqun Hu, who contribute to the research and development processes at Suzhou Stainwei Biotech Inc.
Conclusion
Xiaoya Ping's contributions to monoclonal antibody research exemplify the innovative spirit in biotechnology. His work holds promise for improving treatment options for various cancers, showcasing the importance of continued research in this vital field.